In HER2-positive breast cancer, treatment paradigms have been revolutionized by next-generation antibody-drug conjugates, advanced antibody formats, and technologies facilitating drug penetration across the blood-brain barrier, collectively improving systemic and central nervous system disease control. This evidence concerns the gene ERBB2 and breast cancer.